Building Adaptive Coping and Knowledge to Improve Daily Life (Back2Life): A Pilot Feasibility Trial for Youth with Chronic Sickle Cell Pain

Introduction: Cognitive-behavioral therapy (CBT) for pain is an effective non-pharmacological treatment for chronic pain management, yet can have limited generalizability, access, and reach for underrepresented populations like youth with sickle cell disease (SCD). We aimed to conduct a single-arm p...

Full description

Saved in:
Bibliographic Details
Published in:Blood Vol. 142; no. Supplement 1; p. 3734
Main Authors: Sil, Soumitri, Ifendu, Nwanna, Mooney, Jan, Shneider, Caitlin, Kelling, Erin, Quast, Lauren, Ellzey, Delilah, Manikowski, Alison, Schneider Hughes, Mallory, Dampier, Carlton, Cohen, Lindsey L
Format: Journal Article
Language:English
Published: Elsevier Inc 02-11-2023
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Introduction: Cognitive-behavioral therapy (CBT) for pain is an effective non-pharmacological treatment for chronic pain management, yet can have limited generalizability, access, and reach for underrepresented populations like youth with sickle cell disease (SCD). We aimed to conduct a single-arm proof-of-concept clinical trial to evaluate the feasibility, acceptability, and preliminary efficacy of Back2Life, an adapted, culturally congruent CBT intervention for youth with chronic SCD pain and their parents. We hypothesized that Back2Life would be feasible and acceptable as demonstrated by high levels of treatment engagement (≥80% attendance of treatment sessions) and satisfaction. We also expected clinically significant reductions in pain and pain interference and improvements in pain coping efficacy from baseline to 3-month follow-up (primary endpoint) and 6-month follow-up (maintenance endpoint). Methods: Youth receiving care at comprehensive SCD clinics at 3 tertiary care locations within a southeast children's hospital were included if they were aged 10-18 years, any SCD genotype, reported chronic pain (i.e., pain on most days per month for at least 3 months), had English fluency, and had stable disease-modifying treatments in the past 3 months. Youth were excluded if they had comorbid medical conditions typically associated with pain but unrelated to SCD, had significant cognitive or developmental limitations that would interfere with study procedures, or received ≥ 3 sessions of outpatient psychological therapy for pain management in the preceding 6 months. Patients completed assessments at baseline, post-treatment, 3-month follow-up, and 6-month follow-up. Primary outcomes included pain characteristics (i.e., intensity, frequency, burden), pain interference, and coping self-efficacy. Secondary outcomes included depressive symptoms, pain catastrophizing, and sleep quality. The Back2Life program included evidence-based CBT treatment manuals that were adapted based on qualitative feedback from patient and parent stakeholders to optimize the cultural congruence and relevance to chronic SCD pain. Back2Life was an adaptive treatment comprised of 6-10 module-based sessions delivered by a behavioral health coach via telehealth. All participants received 6 core sessions and up to 4 additional sessions were included to optimize tailored treatment components to address individual family needs. Tailored sessions targeted common co-morbidities associated with chronic pain and were identified based on findings of the baseline assessment. Families also could opt-in to tailored sessions based on interest. Descriptive statistics were conducted to evaluate feasibility and acceptability metrics as well as clinically significant changes in primary and secondary clinical outcomes. Results: Youth (n=20) were on average 15.9 years old (SD=1.6), 50% female, 100% Black or African American, and 95% Non-Hispanic/Latinx. Most (80%) had hemoglobin types HbSS or HbSβ 0. Feasibility and acceptability ratings were high, including 85% consent rate, 80% initiated study procedures, 100% treatment session completion, 93% intervention fidelity, 100% reported moderate-high treatment satisfaction, and strong qualitative feedback suggested treatment acceptance. Patients reported clinically significant changes from baseline to 6-month follow-up in pain frequency (>35% reduction), worst and typical pain intensities (>30% reduction), SCD pain burden (>30% reduction), pain interference (moderate to mild severity), and improvement in pain coping self-efficacy (see Table 1). Patients also reported changes in pain catastrophizing (high to moderate severity), depressive symptoms (mild severity to within normal limits), and no change in sleep quality. Conclusions: The Back2Life treatment program demonstrated high feasibility and acceptability, participant engagement, participant retention, and meaningful changes in patient-reported outcomes. An adapted, culturally congruent, telehealth-delivered CBT for pain intervention tailored to meet the unique needs experienced by youth with chronic SCD pain can promote increased access, reach, and health equity in SCD. No relevant conflicts of interest to declare. [Display omitted]
AbstractList Introduction: Cognitive-behavioral therapy (CBT) for pain is an effective non-pharmacological treatment for chronic pain management, yet can have limited generalizability, access, and reach for underrepresented populations like youth with sickle cell disease (SCD). We aimed to conduct a single-arm proof-of-concept clinical trial to evaluate the feasibility, acceptability, and preliminary efficacy of Back2Life, an adapted, culturally congruent CBT intervention for youth with chronic SCD pain and their parents. We hypothesized that Back2Life would be feasible and acceptable as demonstrated by high levels of treatment engagement (≥80% attendance of treatment sessions) and satisfaction. We also expected clinically significant reductions in pain and pain interference and improvements in pain coping efficacy from baseline to 3-month follow-up (primary endpoint) and 6-month follow-up (maintenance endpoint). Methods: Youth receiving care at comprehensive SCD clinics at 3 tertiary care locations within a southeast children's hospital were included if they were aged 10-18 years, any SCD genotype, reported chronic pain (i.e., pain on most days per month for at least 3 months), had English fluency, and had stable disease-modifying treatments in the past 3 months. Youth were excluded if they had comorbid medical conditions typically associated with pain but unrelated to SCD, had significant cognitive or developmental limitations that would interfere with study procedures, or received ≥ 3 sessions of outpatient psychological therapy for pain management in the preceding 6 months. Patients completed assessments at baseline, post-treatment, 3-month follow-up, and 6-month follow-up. Primary outcomes included pain characteristics (i.e., intensity, frequency, burden), pain interference, and coping self-efficacy. Secondary outcomes included depressive symptoms, pain catastrophizing, and sleep quality. The Back2Life program included evidence-based CBT treatment manuals that were adapted based on qualitative feedback from patient and parent stakeholders to optimize the cultural congruence and relevance to chronic SCD pain. Back2Life was an adaptive treatment comprised of 6-10 module-based sessions delivered by a behavioral health coach via telehealth. All participants received 6 core sessions and up to 4 additional sessions were included to optimize tailored treatment components to address individual family needs. Tailored sessions targeted common co-morbidities associated with chronic pain and were identified based on findings of the baseline assessment. Families also could opt-in to tailored sessions based on interest. Descriptive statistics were conducted to evaluate feasibility and acceptability metrics as well as clinically significant changes in primary and secondary clinical outcomes. Results: Youth (n=20) were on average 15.9 years old (SD=1.6), 50% female, 100% Black or African American, and 95% Non-Hispanic/Latinx. Most (80%) had hemoglobin types HbSS or HbSβ 0. Feasibility and acceptability ratings were high, including 85% consent rate, 80% initiated study procedures, 100% treatment session completion, 93% intervention fidelity, 100% reported moderate-high treatment satisfaction, and strong qualitative feedback suggested treatment acceptance. Patients reported clinically significant changes from baseline to 6-month follow-up in pain frequency (>35% reduction), worst and typical pain intensities (>30% reduction), SCD pain burden (>30% reduction), pain interference (moderate to mild severity), and improvement in pain coping self-efficacy (see Table 1). Patients also reported changes in pain catastrophizing (high to moderate severity), depressive symptoms (mild severity to within normal limits), and no change in sleep quality. Conclusions: The Back2Life treatment program demonstrated high feasibility and acceptability, participant engagement, participant retention, and meaningful changes in patient-reported outcomes. An adapted, culturally congruent, telehealth-delivered CBT for pain intervention tailored to meet the unique needs experienced by youth with chronic SCD pain can promote increased access, reach, and health equity in SCD.
Introduction: Cognitive-behavioral therapy (CBT) for pain is an effective non-pharmacological treatment for chronic pain management, yet can have limited generalizability, access, and reach for underrepresented populations like youth with sickle cell disease (SCD). We aimed to conduct a single-arm proof-of-concept clinical trial to evaluate the feasibility, acceptability, and preliminary efficacy of Back2Life, an adapted, culturally congruent CBT intervention for youth with chronic SCD pain and their parents. We hypothesized that Back2Life would be feasible and acceptable as demonstrated by high levels of treatment engagement (≥80% attendance of treatment sessions) and satisfaction. We also expected clinically significant reductions in pain and pain interference and improvements in pain coping efficacy from baseline to 3-month follow-up (primary endpoint) and 6-month follow-up (maintenance endpoint). Methods: Youth receiving care at comprehensive SCD clinics at 3 tertiary care locations within a southeast children's hospital were included if they were aged 10-18 years, any SCD genotype, reported chronic pain (i.e., pain on most days per month for at least 3 months), had English fluency, and had stable disease-modifying treatments in the past 3 months. Youth were excluded if they had comorbid medical conditions typically associated with pain but unrelated to SCD, had significant cognitive or developmental limitations that would interfere with study procedures, or received ≥ 3 sessions of outpatient psychological therapy for pain management in the preceding 6 months. Patients completed assessments at baseline, post-treatment, 3-month follow-up, and 6-month follow-up. Primary outcomes included pain characteristics (i.e., intensity, frequency, burden), pain interference, and coping self-efficacy. Secondary outcomes included depressive symptoms, pain catastrophizing, and sleep quality. The Back2Life program included evidence-based CBT treatment manuals that were adapted based on qualitative feedback from patient and parent stakeholders to optimize the cultural congruence and relevance to chronic SCD pain. Back2Life was an adaptive treatment comprised of 6-10 module-based sessions delivered by a behavioral health coach via telehealth. All participants received 6 core sessions and up to 4 additional sessions were included to optimize tailored treatment components to address individual family needs. Tailored sessions targeted common co-morbidities associated with chronic pain and were identified based on findings of the baseline assessment. Families also could opt-in to tailored sessions based on interest. Descriptive statistics were conducted to evaluate feasibility and acceptability metrics as well as clinically significant changes in primary and secondary clinical outcomes. Results: Youth (n=20) were on average 15.9 years old (SD=1.6), 50% female, 100% Black or African American, and 95% Non-Hispanic/Latinx. Most (80%) had hemoglobin types HbSS or HbSβ 0. Feasibility and acceptability ratings were high, including 85% consent rate, 80% initiated study procedures, 100% treatment session completion, 93% intervention fidelity, 100% reported moderate-high treatment satisfaction, and strong qualitative feedback suggested treatment acceptance. Patients reported clinically significant changes from baseline to 6-month follow-up in pain frequency (>35% reduction), worst and typical pain intensities (>30% reduction), SCD pain burden (>30% reduction), pain interference (moderate to mild severity), and improvement in pain coping self-efficacy (see Table 1). Patients also reported changes in pain catastrophizing (high to moderate severity), depressive symptoms (mild severity to within normal limits), and no change in sleep quality. Conclusions: The Back2Life treatment program demonstrated high feasibility and acceptability, participant engagement, participant retention, and meaningful changes in patient-reported outcomes. An adapted, culturally congruent, telehealth-delivered CBT for pain intervention tailored to meet the unique needs experienced by youth with chronic SCD pain can promote increased access, reach, and health equity in SCD. No relevant conflicts of interest to declare. [Display omitted]
Author Ifendu, Nwanna
Kelling, Erin
Mooney, Jan
Cohen, Lindsey L
Dampier, Carlton
Ellzey, Delilah
Quast, Lauren
Shneider, Caitlin
Sil, Soumitri
Schneider Hughes, Mallory
Manikowski, Alison
Author_xml – sequence: 1
  givenname: Soumitri
  surname: Sil
  fullname: Sil, Soumitri
  organization: Emory University/Children's Healthcare of Atlanta, Atlanta, GA
– sequence: 2
  givenname: Nwanna
  surname: Ifendu
  fullname: Ifendu, Nwanna
  organization: Children's Healthcare of Atlanta, Atlanta, GA
– sequence: 3
  givenname: Jan
  surname: Mooney
  fullname: Mooney, Jan
  organization: Emory University/Children's Healthcare of Atlanta, Atlanta, GA
– sequence: 4
  givenname: Caitlin
  surname: Shneider
  fullname: Shneider, Caitlin
  organization: Georgia State University, Atlanta, GA
– sequence: 5
  givenname: Erin
  surname: Kelling
  fullname: Kelling, Erin
  organization: Children's Hospital Colorado, Denver, CO
– sequence: 6
  givenname: Lauren
  surname: Quast
  fullname: Quast, Lauren
  organization: Emory University/Children's Healthcare of Atlanta, Atlanta, GA
– sequence: 7
  givenname: Delilah
  surname: Ellzey
  fullname: Ellzey, Delilah
  organization: Children's Healthcare of Atlanta, Atlanta, GA
– sequence: 8
  givenname: Alison
  surname: Manikowski
  fullname: Manikowski, Alison
  organization: UNC Children's Hospital, Chapel Hill, NC
– sequence: 9
  givenname: Mallory
  surname: Schneider Hughes
  fullname: Schneider Hughes, Mallory
  organization: Little Futures LLC, Atlanta, GA
– sequence: 10
  givenname: Carlton
  surname: Dampier
  fullname: Dampier, Carlton
  organization: Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA
– sequence: 11
  givenname: Lindsey L
  surname: Cohen
  fullname: Cohen, Lindsey L
  organization: Georgia State University, Atlanta, GA
BookMark eNp9kM9OwzAMxiMEEmPwANxyhEPBSdM_g9MoDBCTQGIcOFVp4g5DaKa0G9oz8NJ0jDMX25-sz5_1O2C7jW-QsWMBZ0Lk8rxy3ttIgoyjXkoV77CBSGQeAUjYZQMASCM1ysQ-O2jbdwChYpkM2PfVkpylZs7HVi86WiEv_GKjdWP5Q-O_HNo58s7z-89F8P3-WpNb8ynVyE-utPmQm_H0go_5Eznf8Qnqlipy1K35LJB2vPaBv_pl98a_qC_FW_ANGf5M5sP1eegcf9LUHLK9WrsWj_76kL1MbmbFXTR9vL0vxtPIiDiLI2OSTIGpAVVep5WCWqUCRJLFtbBpVWGqk1zBKAcYZZhIJQ2A1pBWINDqUTxkYnvXBN-2AetyEehTh3UpoNzQLH9plhua5ZZm77ncerB_bEUYytYQNgYtBTRdaT394_4Bckt-VQ
ContentType Journal Article
Copyright 2023 The American Society of Hematology
Copyright_xml – notice: 2023 The American Society of Hematology
DBID AAYXX
CITATION
DOI 10.1182/blood-2023-182243
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList CrossRef

DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Biology
Anatomy & Physiology
EISSN 1528-0020
EndPage 3734
ExternalDocumentID 10_1182_blood_2023_182243
S0006497123103363
GroupedDBID ---
-~X
.55
0R~
1CY
23N
2WC
34G
39C
4.4
53G
5GY
5RE
6J9
AAEDW
AALRI
AAXUO
ABOCM
ACGFO
ADBBV
AENEX
AFETI
AFOSN
AITUG
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
BAWUL
BTFSW
CS3
DIK
DU5
E3Z
EBS
EJD
EX3
F5P
FDB
FRP
GS5
GX1
IH2
K-O
KQ8
L7B
LSO
MJL
N9A
OK1
P2P
R.V
RHF
RHI
ROL
SJN
THE
TR2
TWZ
W2D
WH7
WOQ
WOW
X7M
YHG
YKV
5VS
AAYXX
ABVKL
CITATION
W8F
ID FETCH-LOGICAL-c1373-cc5740cf0e48f6b40f46101573f1d6bbe6a5840980097e5242c00aa06b01eda93
ISSN 0006-4971
IngestDate Thu Nov 21 22:14:02 EST 2024
Sat Oct 26 15:43:12 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue Supplement 1
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c1373-cc5740cf0e48f6b40f46101573f1d6bbe6a5840980097e5242c00aa06b01eda93
OpenAccessLink https://doi.org/10.1182/blood-2023-182243
PageCount 1
ParticipantIDs crossref_primary_10_1182_blood_2023_182243
elsevier_sciencedirect_doi_10_1182_blood_2023_182243
PublicationCentury 2000
PublicationDate 2023-11-02
PublicationDateYYYYMMDD 2023-11-02
PublicationDate_xml – month: 11
  year: 2023
  text: 2023-11-02
  day: 02
PublicationDecade 2020
PublicationTitle Blood
PublicationYear 2023
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
SSID ssj0014325
Score 2.482602
Snippet Introduction: Cognitive-behavioral therapy (CBT) for pain is an effective non-pharmacological treatment for chronic pain management, yet can have limited...
SourceID crossref
elsevier
SourceType Aggregation Database
Publisher
StartPage 3734
Title Building Adaptive Coping and Knowledge to Improve Daily Life (Back2Life): A Pilot Feasibility Trial for Youth with Chronic Sickle Cell Pain
URI https://dx.doi.org/10.1182/blood-2023-182243
Volume 142
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtZ1ba9RAFMeHbUXri-hWsd44DyrqEsxlcvNtd10p1RYhK-hTmCQzGNompe4i_Qx-ac-ZmSRdqqCCLyEbSGbh_8vMyZlzYexpxIWKE5k4RVpEDpXsxldKKKf0FU9U6LuVoETh_Sw--py8XfDFaNT1NRiu_Vel8RpqTZmzf6F2_1C8gOeoOR5RdTz-ke4z2-d6Mq3EmY4LmpucKPKQv-88aGRyGn-CROHJxfGhVtrcnIny2Kcfz_zUpK1_rE_a1QRtRRtJezFZ6lYfFKD4hTrwGWeuLbM7yWraLZ7MtVNQ2MLe3bbxie1Nr506xv2ctevTenVe95Aq2VRrTel30TT9snHYtjYy7WAgOvvaUKEum8yIY9jxrB_DD3RC3_DV2yfYbMR_0mpKTfC8jQnb1OOyU24QW2-o3Ph5dWlIqNSsSQcw41MAbTCsg310YqYNNRyUbN8giIItds3HeYym0ezgqN-k4oFvGmTY_2g3zfG5r68M82uz55Ips7zNbtlvEJgaeO6wkWzGbHfaiFV7egHPQUcF6-2WMbs-68525l1vwDG7cWhDMnbZjw446IADAxwgcNADB6sWLHCggQNiDF70uL18A1PQqMEl1ECjBogaaNSAUAOLGhjUgFADQu0u-_RusZzvO7bDh1N6KJRTlmHM3VK5EieGqOCuovL_XhgHyquiopCRCMkDkVC6kQzRnCxdVwg3KlxPViIN7rHtBuG7zyAuyqKMPCVFXPAyTRNfci7SVFW8UEEc7rFXnQD5mSnkkusP4MTPtVo5qZUbtfYY7yTKrSVqLMwcafr9bQ_-7baH7ObwQjxi26vztXzMtr5V6ycauJ9rvqfT
link.rule.ids 315,782,786,27933,27934
linkProvider Multiple Vendors
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Building+Adaptive+Coping+and+Knowledge+to+Improve+Daily+Life+%28Back2Life%29%3A+A+Pilot+Feasibility+Trial+for+Youth+with+Chronic+Sickle+Cell+Pain&rft.jtitle=Blood&rft.au=Sil%2C+Soumitri&rft.au=Ifendu%2C+Nwanna&rft.au=Mooney%2C+Jan&rft.au=Shneider%2C+Caitlin&rft.date=2023-11-02&rft.pub=Elsevier+Inc&rft.issn=0006-4971&rft.volume=142&rft.spage=3734&rft.epage=3734&rft_id=info:doi/10.1182%2Fblood-2023-182243&rft.externalDocID=S0006497123103363
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon